Jacobs Journal of Diabetes and Endocrinology
Articles in Press
Volume 1 Issue 2
Leptin Resistance and Insulin Resistance Go Hand In Hand, but Lipids are Left Behind
Djordje S. Popovic, MD*, Dragana Tomic-Naglic, MD, PhD, Milena Mitrovic, MD, PhD, Tijana Icin, MD, PhD, Ivana Bajkin, MD, Biljana Srdic-Galic, MD, PhD, Jovanka Novakovic-Paro, MD, PhD, Maja Ruzic, MD, PhD, Bojan Vukovic, MD, Edita Stokic, MD, PhD
Leptin is a hormone secreted by adipose tissue in direct proportion to amount of body fat and it regulates energy homeostasis. Leptin resistance is often associated with insulin resistance and lipid metabolism disorders in obese persons. Study investigates correlation of leptinemia with insulin resistance, and lipid and lipoprotein metabolism parameters in obesity. Study included 60 obese patients. The most common endocrine causes of obesity (hypothyroidism, hyperprolactinemia, hypercortisolism and insulinoma) were eliminated.
MCPIP1 Deficiency Increases Insulin Sensitivity But Impairs Hepatic Insulin Signal Transduction in Mice
Brett B. Holdaway, Joshua D. Moody, Lauren F. Brooks, Mingui Fu, Pappachan Kolattukudy, and Yingzi Chang*
Chronic inflammation is associated with pathogenesis of metabolic disorders, including insulin resistance. MCPIP1 (monocyte chemotactic protein [MCP]–induced protein 1; also known as ZC3H12A) is a newly discovered RNase that is essential in controlling inflammatory response and immune homeostasis. Our current study was designed to test if MCPIP1 deficiency affects glucose homeostasis by regulating the insulin signal transduction pathway in liver and/or adipose tissue, the two major organs that are involved in maintaining glucose homeostasis.
Continuous Glucose Monitoring Assessment of Glucose Variability with Liraglutide add-on or Substitution in T2DM during 24 hour and 3 hour
Paul M. Rosman, DO, Jeffrey S. Freeman*, DO, Jayme A. Aschemeyer, DO, David M. Capuzzi, MD, PHD
Medication add-ons and substitutions used commonly to improve glucose management in people with diabetes may create unforeseen interactions that complicate patient care. We addressed this concern using Continuous Glucose Monitoring (CGM) from which we measured glycemic variability as a metric of successful add-on or substitution. Additionally, we compared calculated HbA1c differences between pre liraglutide and post liraglutide treatment mean 24 hour studies. Lastly, we looked at hypoglycemic predictability as a tool to evaluate patient safety when add-ons or substitutions occur.
Effects of Lifestyle Modification Program, KOHNODAI Program, on Metabolic Parameters in Japanese Obese People
Akiko Kawaguchi, MD, Hisayuki Katsuyama, MD, PhD, Hidekatsu Yanai, MD, PhD*
We developed the program to support obese patients to change their lifestyle related with obesity, KOHNODAI program. Here we studied effects of KOHNODAI program on metabolic parameters in 19 Japanese obese people. Mean body weight significantly decreased to 79.9 kg immediately after the KOHNODAI program, and at 3 (79.7 kg) and 6 months (77.3 kg) after the program as compared with body weight before the program (81.7 kg). Serum high-density lipoprotein-cholesterol levels significantly increased, and alanine aminotransferase tended to decrease 6 months after the program.